LLY shares have bounced cleanly off a technical demand zone and cleared prior highs, with upside targets near $1,000 driven by gamma exposure, even as FDA approval spikes fueled strong call buying and elevated implied volatility. Intraday pops of 4–6% on drug approvals have been met by pockets of profit-taking and political selling pressure, underscoring both pronounced buying flows and intermittent selling liquidity.

Mounjaro and Zepbound drove GLP-1 sales to over $36 billion in 2025, fueling 42.6 % Q4 revenue growth and 44.7 % full-year growth to $65.2 billion. Oral GLP-1 pill Foundayo received FDA approval and is rolling out broadly through retail and digital channels, targeting a $50 billion+ oral obesity market. Lilly’s efficient scale-up—including new Virginia capacity—supports 2026 guidance of $80–83 billion in revenue.

FDA approval of Eli Lilly’s daily oral GLP-1 pill Foundayo extends the once-injectable obesity treatment class alongside Novo Nordisk’s Wegovy, while Trump-era Most Favored Nation pricing deals and Medicare coverage initiatives force manufacturers into concessions or risk steep tariffs, driving onshoring and capacity investments and shaping global launch timelines under evolving IP protections and supply-chain incentives.

Investor enthusiasm around Lilly’s oral GLP-1 pills has surged, with many expecting Foundayo’s swift approvals, positive efficacy signals, and broad distribution to carve out market share and drive revenue into the billions. Analysts have largely raised price targets and reinforce a strong-buy consensus, fueling belief in a multi-billion-dollar obesity market, even as comparisons to Novo Nordisk’s oral Wegovy invite debate over which therapy patients will prefer.

Shares have experienced notable volatility, trading near $930 after a roughly 7% post-reporting drop and off about 15% year-to-date, even as a modest 0.11% pre-market uptick pushed the price toward $986. Options activity is elevated, with nearly 20,000 contracts changing hands—about 52.5% of average daily volume—while passive funds like Elfun Trusts slashed their LLY holdings by nearly 31%.

GLP-1 therapies Mounjaro and Zepbound drove volume-led revenue above $65 billion in 2025 (YoY growth ~43%), enabling full-year 2026 guidance of $80–83 billion and non-GAAP EPS up to $35.00. Robust cash flow supports a $55 billion-plus manufacturing expansion since 2020, competitive margins, and targeted investments—from the $6.3 billion Centessa buy to AI drug-discovery partnerships—to broaden the pipeline across neuroscience, immunology, and oncology.

Eli Lilly is bolstering global manufacturing by funding local production hubs in China and new U.S. plants to support its obesity and diabetes pipeline, even as FDA crackdowns on compounded GLP-1 formulations and CMS’s BALANCE and Medicare Part D pricing models impose tighter regulatory and cost-sharing constraints. Ongoing third-party payor litigation and evolving employer-sponsored subscription platforms layer legal and access hurdles, while a duopoly with Novo Nordisk faces intensifying government-driven pricing pressure.

Eli Lilly’s GLP-1 weight-loss success has fueled investor enthusiasm, with expectations for sustained blockbuster growth driving bullish narratives around AI partnerships, neuroscience acquisitions, and pipeline diversification. At the same time, concerns over lofty valuations, regulatory and FDA approval risks, intensifying competition, price concessions, and safety issues for compounded alternatives temper sentiment, leaving a tense balance between optimism and caution.

Eli Lilly shares have rallied sharply on early earnings release and trial wins, trading above key support levels, drawing heavy options volume—including elevated put activity—and attracting fund buying, while Novo Nordisk has faced steep premarket selling after its obesity drug underperformed in head-to-head trials.

GLP-1 therapies Mounjaro and Zepbound now account for over 50% of revenue, driving exceptional growth—with quarterly sales up more than 40% year-over-year and 2026 revenue guidance of $80–83 billion (≈25% growth). Lilly is expanding production capacity through over $9.5 billion in U.S. manufacturing investments, a $1.5 billion pre-launch inventory build for its oral GLP-1 candidate, and new facilities in India, while late-stage and pipeline programs in diabetes, obesity, and immunology support sustained margin expansion and future product ramps.

Regulatory filings for oral and injectable GLP-1 therapies span more than 40 countries, with U.S. approvals expected in Q2 2026 and launches planned through 2027. Government pricing initiatives—including TrumpRx discount deals and Medicare negotiations under the IRA—are reshaping reimbursement for Zepbound, Mounjaro and Wegovy, while price cuts by Novo are intensifying competitive pressure. Companies are expanding manufacturing capacity in India and Pennsylvania, and striking licensing and acquisition deals—such as Lilly’s $2.4 billion Orna buy and $350 million Innovent pact—to secure supply chains and diversify beyond obesity drugs. Head-to-head trial outcomes and non-inferiority failures are already influencing market positioning and pricing strategies.

Investors are highly optimistic about Eli Lilly’s leadership in obesity treatments, rewarding strong trial results, bullish guidance, and a diversified pipeline with premium valuations and rising price targets, while growing skepticism surrounds Novo Nordisk after its CagriSema underperformed rival tirzepatide, underscoring pressure on its GLP-1 franchise amid fierce competition and pricing debates. Crowd psychology remains upbeat overall but tempered by nervousness over elevated expectations.

—

Return on invested capital has climbed to 22.4%, supported by consistent R&D spending of roughly 25–38% of revenue and billion-dollar deal-making capacity, while drug demand still outpaces current supply.

Eli Lilly is expanding manufacturing capacity with a $3.5 billion injectable drug and device plant in Pennsylvania, secured a Trump administration pricing deal for weight-loss drugs, and expects oral obesity treatment approval by Q2, while forming licensing and development partnerships (Nimbus, Scorpion, Ventec) amid intensifying GLP-1 competition from Novo Nordisk, Pfizer and Amgen.

Optimism around mid-2026 FDA approval for Lilly’s weight-loss pill is paired with buzz over a potential billion-dollar takeover and a $1 billion AI partnership with Nvidia, while CEO talk of a $1 trillion valuation and record dealmaking fuels upbeat sentiment even as regulatory timelines and bid details keep some caution.